Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Chemed Corp can feel like tackling two companies at once: hospice care economics in VITAS and emergency plumbing metrics in Roto-Rooter. That split shows up in every 10-K footnote, Form 4 footnote, and 8-K headline, making Chemed’s SEC filings unusually dense.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the latest Chemed quarterly earnings report 10-Q filing or want Chemed Form 4 insider transactions real-time, our platform surfaces the numbers and narrative in plain language. Instantly pinpoint hospice reimbursement rate disclosures, segment operating margins, and technician labor costs—without wading through hundreds of pages.
All Chemed filings arrive minutes after EDGAR posts. Click into:
- 10-K annual report—AI highlights VITAS patient census trends and Roto-Rooter service revenue (Chemed annual report 10-K simplified).
- 10-Q quarterly update—Compare sequential hospice margins with a one-click Chemed earnings report filing analysis.
- 8-K material events—Get alerts when Medicare rules change (Chemed 8-K material events explained).
- Form 4—Monitor executive stock moves, including CEO transactions (Chemed insider trading Form 4 transactions, Chemed executive stock transactions Form 4).
- Proxy statement (DEF 14A)—Understand how compensation aligns with both segments (Chemed proxy statement executive compensation).
Need context fast? Our summaries answer common questions like “understanding Chemed SEC documents with AI” or “where can I find Chemed’s hospice segment revenue?”. Save hours, stay informed, and make confident decisions with filings explained simply.
Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.
Chemed Corp. (CHE) Form 4 filing: Director George J. Walsh III purchased 200 shares of Chemed common stock on 08/04/2025 at $417.10 per share, an outlay of roughly $83,420. His direct holdings rise to 3,523 shares; he also reports 434 shares held indirectly by his spouse. No shares were sold and no derivative positions were opened or closed. The transaction modestly increases the director’s exposure—about a 6% lift in his direct stake—while leaving total company share count essentially unaffected. Insider buying by a non-executive director is often interpreted as a vote of confidence, though the amount is immaterial compared to Chemed’s ~15 million shares outstanding.
Chemed Corporation (NYSE: CHE) filed a Form 8-K on June 27, 2025 to furnish a Regulation FD disclosure.
- Material event: The Company issued a press release (Exhibit 99) stating it now expects second-quarter 2025 earnings to be lower than previously anticipated and is reducing its full-year 2025 earnings guidance.
- The filing does not include specific dollar amounts, revised EPS figures or updated revenue ranges; only the direction of the change is disclosed.
- No other operational changes, financings, or acquisitions were reported in the filing.
- The press release itself is furnished, not filed, preserving safe-harbor protections for forward-looking statements.
Because the Company is signalling weaker performance and a downward revision to outlook, the disclosure is materially negative for investors, implying potential pressure on near-term financial results and valuation multiples. Investors will need to review the full press release and forthcoming Q2 results to quantify the impact.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
